ES2572355A2 - Combinacion de aad para uso en el tratamiento del vhc - Google Patents
Combinacion de aad para uso en el tratamiento del vhcInfo
- Publication number
- ES2572355A2 ES2572355A2 ES201431521A ES201431521A ES2572355A2 ES 2572355 A2 ES2572355 A2 ES 2572355A2 ES 201431521 A ES201431521 A ES 201431521A ES 201431521 A ES201431521 A ES 201431521A ES 2572355 A2 ES2572355 A2 ES 2572355A2
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- hcv
- translation
- combination
- machine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
Abstract
Combinación de AAD para uso en el tratamiento del VHC. La presente invención presenta combinaciones de agentes antivirales para uso en terapias sin interferón y ribavirina en el tratamiento de VHC. Preferentemente, el tratamiento es durante un tiempo de tratamiento corto, tal como no más de 12 semanas. En un aspecto, el uso de las combinaciones de agentes antivirales en las terapias comprende administrar al menos dos agentes antivirales de acción directa sin interferón y ni ribavirina a un sujeto con infección por VHC.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161055036P | 2011-10-21 | 2011-10-21 | |
US61/55036 | 2011-10-21 | ||
US201161056217P | 2011-11-21 | 2011-11-21 | |
US61/56217 | 2011-11-21 | ||
US201261058719P | 2012-01-17 | 2012-01-17 | |
US61/58719 | 2012-01-17 | ||
US201261060046P | 2012-02-17 | 2012-02-17 | |
US61/60046 | 2012-02-17 | ||
US201261061988P | 2012-04-03 | 2012-04-03 | |
US61/61988 | 2012-04-03 | ||
US201261065625P | 2012-06-06 | 2012-06-06 | |
US61/65625 | 2012-06-06 | ||
US201261071179P | 2012-10-10 | 2012-10-10 | |
US61/71179 | 2012-10-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2572355A2 true ES2572355A2 (es) | 2016-05-31 |
ES2572355R1 ES2572355R1 (es) | 2016-11-03 |
ES2572355B1 ES2572355B1 (es) | 2017-08-24 |
Family
ID=52465028
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201490005A Expired - Fee Related ES2529144B1 (es) | 2011-10-21 | 2012-10-19 | Combinación de aad para uso en el tratamiento del vhc |
ES201431521A Withdrawn - After Issue ES2572355B1 (es) | 2011-10-21 | 2012-10-19 | Combinación de aad para uso en el tratamiento del vhc |
ES201431520A Withdrawn - After Issue ES2572330B1 (es) | 2011-10-21 | 2012-10-19 | Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201490005A Expired - Fee Related ES2529144B1 (es) | 2011-10-21 | 2012-10-19 | Combinación de aad para uso en el tratamiento del vhc |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201431520A Withdrawn - After Issue ES2572330B1 (es) | 2011-10-21 | 2012-10-19 | Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc |
Country Status (1)
Country | Link |
---|---|
ES (3) | ES2529144B1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819459B (zh) * | 2009-06-11 | 2017-05-17 | 艾伯维巴哈马有限公司 | 抗病毒化合物 |
WO2011112558A2 (en) * | 2010-03-10 | 2011-09-15 | Abbott Laboratories | Solid compositions |
-
2012
- 2012-10-19 ES ES201490005A patent/ES2529144B1/es not_active Expired - Fee Related
- 2012-10-19 ES ES201431521A patent/ES2572355B1/es not_active Withdrawn - After Issue
- 2012-10-19 ES ES201431520A patent/ES2572330B1/es not_active Withdrawn - After Issue
Also Published As
Publication number | Publication date |
---|---|
ES2572330B1 (es) | 2017-08-24 |
ES2572355R1 (es) | 2016-11-03 |
ES2529144A2 (es) | 2015-02-17 |
ES2572355B1 (es) | 2017-08-24 |
ES2529144R1 (es) | 2015-03-10 |
ES2529144B1 (es) | 2015-10-26 |
ES2572330A2 (es) | 2016-05-31 |
ES2572330R1 (es) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2572329A2 (es) | Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc | |
MX2020005054A (es) | Combinacion de dos agentes antivirales para el tratamiento de hepatitis c. | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
IN2012MN02896A (es) | ||
MX2013003060A (es) | Terapia de combinacion para tratar infeccion por hcv. | |
CY1109685T1 (el) | Χρησιμοποιηση συμπλοκων ενωσεων σιδηρου(ιιι) | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
TN2011000204A1 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2010013019A (es) | Sales antivirales. | |
ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc | |
NZ602552A (en) | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside | |
EA201491652A1 (ru) | Средство для лечения вирусного гепатита с | |
TN2013000134A1 (en) | Combination therapy for treating hcv infection | |
NZ620689A (en) | Hcv immunotherapy | |
UA73960U (ru) | Способ лечения хронического гепатита с с генотипами вируса 2 или 3 у вич-инфицированных лиц |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2572355 Country of ref document: ES Kind code of ref document: B1 Effective date: 20170824 |
|
FA2A | Application withdrawn |
Effective date: 20180212 |